Kazia Therapeutics Ltd Sponsored ADR Forecast, price target & analysts
Kazia Therapeutics Ltd Sponsored ADR Target price 2025 - Analyst rating & recommendation
Kazia Therapeutics Ltd Sponsored ADR Classifications & Recommendation:
Kazia Therapeutics Ltd Sponsored ADR Price Target
| Target Price | $14.28 |
| Price | $7.88 |
| Potential |
81.22%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Kazia Therapeutics Ltd Sponsored ADR 2026 .
The average Kazia Therapeutics Ltd Sponsored ADR target price is $14.28.
This is
81.22%
register free of charge
$15.75
99.87%
register free of charge
$13.13
66.62%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Kazia Therapeutics Ltd Sponsored ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kazia Therapeutics Ltd Sponsored ADR stock has an average upside potential 2026 of
81.22%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.53 | 0.02 |
| 15,200.00% | 98.53% | |
| EBITDA Margin | -1,089.54% | 21,071.12% |
| 2,033.94% | ||
| Net Margin | -1,151.63% | -7,505,074.63% |
| 99.15% | 651,589.23% |
4 Analysts have issued a sales forecast Kazia Therapeutics Ltd Sponsored ADR 2025 . The average Kazia Therapeutics Ltd Sponsored ADR sales estimate is
This results in the following potential growth metrics:
3 Kazia Therapeutics Ltd Sponsored ADR Analysts have issued a net profit forecast 2025. The average Kazia Therapeutics Ltd Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.33 | -17.45 |
| 90.96% | 5,187.88% | |
| P/E | negative | |
| EV/Sales | 431.81 |
3 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast for earnings per share. The average Kazia Therapeutics Ltd Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Kazia Therapeutics Ltd Sponsored ADR...
Current Kazia Therapeutics Ltd Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Jun 11 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 10 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Jun 11 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Feb 06 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
